Magle Chemoswed Holding
17.40 SEK
-4.92 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-4.92 %
-8.90 %
-19.44 %
-37.41 %
-50.00 %
-48.52 %
-34.82 %
-47.70 %
-13.40 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
359.3M SEK
Turnover
35.23K SEK
Revenue
236.04M
EBIT %
9.84 %
P/E
0.4
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
Magle Chemoswed Holding Announces Chairman Transition
Magle Group Completes European Medical Device Filing for the Use of EmboCept® S in Genicular Artery Embolisation
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools